1-20 of 28
David A. Reardon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma

Fabio M. Iwamoto, Shyam K. Tanguturi, Lakshmi Nayak, Tony J. Wang, Arati Desai, Robert A. Lustig, Stephen Bagley, Eric T. Wong, Lauren M. Hertan, Christine McCluskey, Julia Hayden, Alona Muzikansky, Shreya Nakhawa, Julia Japo, Connor C. Bossi, Maxime Meylan, Ye Tian, Graham L. Barlow, Paul Speliakos, Georges Ayoub, David M. Meredith, Keith L. Ligon, Daphne Haas-Kogan, Kun Huang, Kai W. Wucherpfennig, Patrick Y. Wen, David A. Reardon
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (2): 316–327.
https://doi.org/10.1158/1078-0432.CCR-24-1629
Published: 17 January 2025
View article titled, Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Open the PDF for Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma

Mary Jane Lim-Fat, J. Bryan Iorgulescu, Rifaquat Rahman, Varun Bhave, Alona Muzikansky, Eleanor Woodward, Sydney Whorral, Marie Allen, Mehdi Touat, Xiaomei Li, Gongwen Xy, Jay Patel, Elizabeth R. Gerstner, Jayashree Kalpathy-Cramer, Gilbert Youssef, Ugonma Chukwueke, J. Ricardo McFaline-Figueroa, Lakshmi Nayak, Eudocia Q. Lee, David A. Reardon, Rameen Beroukhim, Raymond Y. Huang, Wenya Linda Bi, Keith L. Ligon, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1327–1337.
https://doi.org/10.1158/1078-0432.CCR-23-3018
Published: 01 April 2024
View article titled, Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma
Open the PDF for Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients

K. Ina Ly, Leland G. Richardson, Mofei Liu, Alona Muzikansky, Jonathan Cardona, Kevin Lou, Andrew L. Beers, Ken Chang, James M. Brown, Xiaoyue Ma, David A. Reardon, Isabel C. Arrillaga-Romany, Deborah A. Forst, Justin T. Jordan, Eudocia Q. Lee, Jorg Dietrich, Lakshmi Nayak, Patrick Y. Wen, Ugonma Chukwueke, Anita Giobbie-Hurder, Bryan D. Choi, Tracy T. Batchelor, Jayashree Kalpathy-Cramer, William T. Curry, Elizabeth R. Gerstner
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3017–3025.
https://doi.org/10.1158/1078-0432.CCR-23-0203
Published: 15 August 2023
View article titled, Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
Open the PDF for Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients in another window
Includes: Supplementary data
Journal Articles

Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors

Joseph Toker, J. Bryan Iorgulescu, Alexander L. Ling, Genaro R. Villa, Josephina A.M.A. Gadet, Laxmi Parida, Gad Getz, Catherine J. Wu, David A. Reardon, E. Antonio Chiocca, Marco Mineo
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (12): 2226–2238.
https://doi.org/10.1158/1078-0432.CCR-22-3714
Published: 13 June 2023
View article titled, Clinical Importance of the lncRNA <em>NEAT1</em> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Open the PDF for Clinical Importance of the lncRNA <em>NEAT1</em> in Cancer Patients Treated with Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

Lakshmi Nayak, Nathan Standifer, Jorg Dietrich, Jennifer L. Clarke, Gavin P. Dunn, Michael Lim, Timothy Cloughesy, Hui K. Gan, Elizabeth Flagg, Elizabeth George, Sarah Gaffey, Julia Hayden, Christina Holcroft, Patrick Y. Wen, Mary Macri, Andrew J. Park, Toni Ricciardi, Aileen Ryan, Paul Schwarzenberger, Ralph Venhaus, Melissa de los Reyes, Nicholas M. Durham, Todd Creasy, Raymond Y. Huang, Thomas Kaley, David A. Reardon
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2567–2578.
https://doi.org/10.1158/1078-0432.CCR-21-4064
Published: 13 June 2022
View article titled, Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
Open the PDF for Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma

Kirit Singh, Kristen A. Batich, Patrick Y. Wen, Aaron C. Tan, Stephen J. Bagley, Michael Lim, Michael Platten, Howard Colman, David M. Ashley, Susan M. Chang, Rifaquat Rahman, Evanthia Galanis, Alireza Mansouri, Vinay K. Puduvalli, David A. Reardon, Solmaz Sahebjam, John H. Sampson, John Simes, Donald A. Berry, Gelareh Zadeh, Tim F. Cloughesy, Minesh P. Mehta, Steven Piantadosi, Michael Weller, Amy B. Heimberger, Mustafa Khasraw
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 585–593.
https://doi.org/10.1158/1078-0432.CCR-21-2681
Published: 15 February 2022
View article titled, Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma
Open the PDF for Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma in another window
Journal Articles

Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement

Stephen J. Bagley, Shawn Kothari, Rifaquat Rahman, Eudocia Q. Lee, Gavin P. Dunn, Evanthia Galanis, Susan M. Chang, Louis Burt Nabors, Manmeet S. Ahluwalia, Roger Stupp, Minesh P. Mehta, David A. Reardon, Stuart A. Grossman, Erik P. Sulman, John H. Sampson, Simon Khagi, Michael Weller, Timothy F. Cloughesy, Patrick Y. Wen, Mustafa Khasraw
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 594–602.
https://doi.org/10.1158/1078-0432.CCR-21-2750
Published: 15 February 2022
View article titled, Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement
Open the PDF for Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement in another window
Journal Articles

Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials

Julia Furtner, Michael Weller, Michael Weber, Thierry Gorlia, Burt Nabors, David A. Reardon, Joerg C. Tonn, Roger Stupp, Matthias Preusser
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 129–136.
https://doi.org/10.1158/1078-0432.CCR-21-1987
Published: 05 January 2022
View article titled, Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials
Open the PDF for Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak, Annette M. Molinaro, Katherine Peters, Jennifer L. Clarke, Justin T. Jordan, John de Groot, Leia Nghiemphu, Thomas Kaley, Howard Colman, Christine McCluskey, Sarah Gaffey, Timothy R. Smith, David J. Cote, Mariano Severgnini, Jennifer H. Yearley, Qing Zhao, Wendy M. Blumenschein, Dan G. Duda, Alona Muzikansky, Rakesh K. Jain, Patrick Y. Wen, David A. Reardon
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (4): 1048–1057.
https://doi.org/10.1158/1078-0432.CCR-20-2500
Published: 15 February 2021
View article titled, Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Open the PDF for Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma

J. Bryan Iorgulescu, Prafulla C. Gokhale, Maria C. Speranza, Benjamin K. Eschle, Michael J. Poitras, Margaret K. Wilkens, Kara M. Soroko, Chhayheng Chhoeu, Aine Knott, Yan Gao, Mary Jane Lim-Fat, Gregory J. Baker, Dennis M. Bonal, Quang-Dé Nguyen, Gareth R. L. Grant, Keith L. Ligon, Peter K. Sorger, E. Antonio Chiocca, Ana C. Anderson, Paul T. Kirschmeier, Arlene H. Sharpe, Gordon J. Freeman, David A. Reardon
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 276–287.
https://doi.org/10.1158/1078-0432.CCR-20-2291
Published: 04 January 2021
View article titled, Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma
Open the PDF for Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?

Mustafa Khasraw, David A. Reardon, Michael Weller, John H. Sampson
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5287–5296.
https://doi.org/10.1158/1078-0432.CCR-20-1135
Published: 15 October 2020
View article titled, PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
Open the PDF for PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma? in another window
Journal Articles

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

David A. Reardon, Annick Desjardins, James J. Vredenburgh, Donald M. O'Rourke, David D. Tran, Karen L. Fink, Louis B. Nabors, Gordon Li, Daniela A. Bota, Rimas V. Lukas, Lynn S. Ashby, J. Paul Duic, Maciej M. Mrugala, Scott Cruickshank, Laura Vitale, Yi He, Jennifer A. Green, Michael J. Yellin, Christopher D. Turner, Tibor Keler, Thomas A. Davis, John H. Sampson
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (7): 1586–1594.
https://doi.org/10.1158/1078-0432.CCR-18-1140
Published: 01 April 2020
View article titled, Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Open the PDF for Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial in another window
Includes: Supplementary data
Journal Articles

Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy

Carmela Passaro, Quazim Alayo, Isabel DeLaura, John McNulty, Korneel Grauwet, Hirotaka Ito, Vivek Bhaskaran, Marco Mineo, Sean E. Lawler, Khalid Shah, Maria C. Speranza, William Goins, Eric McLaughlin, Soledad Fernandez, David A. Reardon, Gordon J. Freeman, E. Antonio Chiocca, Hiroshi Nakashima
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (3): 758.
https://doi.org/10.1158/1078-0432.CCR-19-4091
Published: 03 February 2020
View article titled, Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
Open the PDF for Correction: Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy in another window
Journal Articles

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma

Patrick Y. Wen, David A. Reardon, Terri S. Armstrong, Surasak Phuphanich, Robert D. Aiken, Joseph C. Landolfi, William T. Curry, Jay-Jiguang Zhu, Michael Glantz, David M. Peereboom, James M. Markert, Renato LaRocca, Donald M. O'Rourke, Karen Fink, Lyndon Kim, Michael Gruber, Glenn J. Lesser, Edward Pan, Santosh Kesari, Alona Muzikansky, Clemencia Pinilla, Radleigh G. Santos, John S. Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (19): 5799–5807.
https://doi.org/10.1158/1078-0432.CCR-19-0261
Published: 01 October 2019
View article titled, A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
Open the PDF for A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma in another window
Includes: Supplementary data
Journal Articles

The Misclassification of Diffuse Gliomas: Rates and Outcomes

J. Bryan Iorgulescu, Matthew Torre, Maya Harary, Timothy R. Smith, Ayal A. Aizer, David A. Reardon, Jill S. Barnholtz-Sloan, Arie Perry
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2656–2663.
https://doi.org/10.1158/1078-0432.CCR-18-3101
Published: 15 April 2019
View article titled, The Misclassification of Diffuse Gliomas: Rates and Outcomes
Open the PDF for The Misclassification of Diffuse Gliomas: Rates and Outcomes in another window
Journal Articles

Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy

Carmela Passaro, Quazim Alayo, Isabel DeLaura, John McNulty, Korneel Grauwet, Hirotaka Ito, Vivek Bhaskaran, Marco Mineo, Sean E. Lawler, Khalid Shah, Maria C. Speranza, William Goins, Eric McLaughlin, Soledad Fernandez, David A. Reardon, Gordon J. Freeman, E. Antonio Chiocca, Hiroshi Nakashima
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 290–299.
https://doi.org/10.1158/1078-0432.CCR-18-2311
Published: 03 January 2019
View article titled, Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
Open the PDF for Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy in another window
Includes: Supplementary data
Journal Articles

Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma

Eudocia Q. Lee, Dan G. Duda, Alona Muzikansky, Elizabeth R. Gerstner, John G. Kuhn, David A. Reardon, Lakshmi Nayak, Andrew D. Norden, Lisa Doherty, Debra LaFrankie, Jennifer Stefanik, Trupti Vardam, Katrina H. Smith, Christine McCluskey, Sarah Gaffey, Tracy T. Batchelor, Rakesh K. Jain, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4643–4649.
https://doi.org/10.1158/1078-0432.CCR-18-1025
Published: 01 October 2018
View article titled, Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma
Open the PDF for Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma in another window
Journal Articles

Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma

Hiroshi Nakashima, Tran Nguyen, Kazue Kasai, Carmela Passaro, Hirotaka Ito, William F. Goins, Imran Shaikh, Ronald Erdelyi, Reiko Nishihara, Ichiro Nakano, David A. Reardon, Ana C. Anderson, Vijay Kuchroo, E. Antonio Chiocca
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (11): 2574–2584.
https://doi.org/10.1158/1078-0432.CCR-17-2954
Published: 31 May 2018
View article titled, Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma
Open the PDF for Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma in another window
Includes: Supplementary data
Journal Articles

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab

Raymond Y. Huang, Rifaquat Rahman, Karla V. Ballman, Sara J. Felten, S. Keith Anderson, Benjamin M. Ellingson, Lakshmi Nayak, Eudocia Q. Lee, Lauren E. Abrey, Evanthia Galanis, David A. Reardon, Whitney B. Pope, Timothy F. Cloughesy, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (3): 575–581.
https://doi.org/10.1158/1078-0432.CCR-14-3040
Published: 31 January 2016
View article titled, The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab
Open the PDF for The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab in another window
Journal Articles

Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects

Tracy T. Batchelor, David A. Reardon, John F. de Groot, Wolfgang Wick, Michael Weller
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5612–5619.
https://doi.org/10.1158/1078-0432.CCR-14-0834
Published: 13 November 2014
View article titled, Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects
Open the PDF for Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects in another window